CDK4 and cancer: More recently, Palbociclib and other CDK4/6 inhibitors (CDK4/6i), in a variety of combinations, have shown efficacy in other cancer types, including colorectal carcinoma [8–24], particularly in tumors bearing genetic or epigenetic alterations underlying an upregulated G1-S cell cycle transition [22, 24].